Tilbake til søkeresultatene

IS-BILAT-Mobilitet Norge-USA /Canada

Proteomic based biomarker discovery in patients with degenerative neurological disorders, infectious disease, and ovarian cancer

Tildelt: kr 0,30 mill.

During his one year stay at the Broad Institute in 2008, Dr Berven will be working in the field of biomarker discovery. He will continue with activities connected to his main project, which is the discovery of disease specific polypeptide biomarkers in th e cerebrospinal fluid from multiple sclerosis patients. Multiple sclerosis has been chosen as a model for developing proteomic biomarkers to improve early diagnostics of degenerative neurological diseases. In addition, he will conduct relevant work in the field of biomarker discovery in plasma and tissue in on-going projects at the Broad Inst., with emphasis on infectious diseases (HIV, malaria and tuberculosis) and ovarian cancer. He will have access to the most modern techniques and mass spectrometric i nstruments which at present are not available in Bergen. A biomarker discovery project with the ultimate goal to develop a new diagnostic assay, goes through the following major phases: 1)the initial candidate discovery phase; 2) the analytical verificati on phase and 3) the clinical validation phase. It is expected that Berven will work within the two first phases during his stay in USA next year. In the discovery phase, disease specific markers are searched for by a thorough comparison of samples from pa tients and controls. Thereafter, candidate markers are verified by examining known and "blinded" samples from patients in different disease stages and from controls. Quantitative / semi-quantitative analysis will be performed for each biomarker in a large r number of samples through alternative strategies using the same type of top modern instrumentation. The bioinformatic analysis of high quality mass spectrometric data is a complex challenge. However, the research group at Broad Inst., MIT do also have a lot of competence and experience in this part of the field. The chance to learn more about bioinformatics of proteomic data and to use unique in-house software will indeed be a great advantage for our own project.

Budsjettformål:

IS-BILAT-Mobilitet Norge-USA /Canada

Finansieringskilder

Temaer og emner

Ingen temaer knyttet til prosjektet